Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers.: Second multicenter study

被引:20
作者
Betriu, Carmen [1 ]
Rodriguez-Avial, Iciar
Gomez, Maria
Culebras, Esther
Lopez, Fatima
Alvarez, Juan
Picazo, Juan J.
机构
[1] Hosp Clin San Carlos, Dept Clin Microbiol, Madrid 28040, Spain
[2] Wyeth Farma, Dept Sci, Madrid 28700, Spain
关键词
tigecycline; activity; bacterial isolates;
D O I
10.1016/j.diagmicrobio.2006.07.005
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The antimicrobial activity of tigecycline, a novel glycylcycline, was evaluated against 1102 bacterial isolates from 20 centers in Spain. The MIC of tigecycline at which 90% (MIC90) of the pneumococci tested were inhibited was the lowest (0.06 mu g/mL) of all the antibiotics tested. The MICs of tigecycline against enterococci ranged from 0.03 to 0.125 mu g/mL. All staphylococci were inhibited by <= 0.25 mu g/mL of tigecycline, and 99.6% of Enterobacteriaceae isolates were inhibited by <= 2 mu g/mL of tigecycline. Tigecycline demonstrated good activity against Bacteroides fragilis group organisms with an MIC90 of 4 mu g/mL. The results of this study confirm the excellent activity of tigecycline against multiresistant Gram-positive and Gram-negative pathogens. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:437 / 444
页数:8
相关论文
共 31 条
[1]  
[Anonymous], M11A6 NCCLS
[2]  
[Anonymous], 2003, NCCLS Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, V6th
[3]   Extended-spectrum β-lactamase-producing Enterobacteriaceae in community and private health care centers [J].
Arpin, C ;
Dubois, V ;
Coulange, L ;
André, C ;
Fischer, I ;
Noury, P ;
Grobost, F ;
Brochet, JP ;
Jullin, J ;
Dutilh, B ;
Larribet, G ;
Lagrange, I ;
Quentin, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (11) :3506-3514
[4]   Drug-resistant pneumococcal pneumonia:: Clinical relevance and related factors [J].
Aspa, J ;
Rajas, O ;
de Castro, FR ;
Blanquer, J ;
Zalacain, R ;
Fenoll, A ;
de Celis, R ;
Vargas, A ;
Salvanés, FR ;
España, PP ;
Rello, J ;
Torres, A .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (06) :787-798
[5]   The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical trial data [J].
Babinchak, T ;
Ellis-Grosse, E ;
Dartois, N ;
Rose, GM ;
Loh, E .
CLINICAL INFECTIOUS DISEASES, 2005, 41 :S354-S367
[6]   Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci [J].
Betriu, C ;
Redondo, M ;
Palau, ML ;
Sánchez, A ;
Gómez, M ;
Culebras, E ;
Boloix, A ;
Picazo, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (07) :1838-1841
[7]   In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain [J].
Betriu, C ;
Rodríguez-Avial, I ;
Sánchez, BA ;
Gómez, M ;
Alvarez, J ;
Picazo, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :892-895
[8]   In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004) [J].
Bouchillon, SK ;
Hoban, DJ ;
Johnson, BM ;
Johnson, JL ;
Hsiung, A ;
Dowzicky, MJ .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2005, 52 (03) :173-179
[9]   Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent Oxyrase to standardize the test method [J].
Bradford, PA ;
Petersen, PJ ;
Young, M ;
Jones, CH ;
Tischler, M ;
O'Connell, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (09) :3903-3909
[10]   Extended-spectrum β-lactamases in the 21st century:: Characterization, epidemiology, and detection of this important resistance threat [J].
Bradford, PA .
CLINICAL MICROBIOLOGY REVIEWS, 2001, 14 (04) :933-951